5 Apr 2026
Partnership With Rezolute Announcement
The Board of Directors of AMEND USA is pleased to recognize and thank Rezolute, Inc. for its support of our 2026 Community Engagement and Development Campaign.
This collaboration reflects a shared commitment to improving awareness, education, and support for individuals and families affected by Multiple Endocrine Neoplasia (MEN) across the United States.
Through this engagement, AMEND USA is leading a comprehensive, community-centered initiative designed to better understand and address the needs of the MEN population. AMEND USA is guided by a multidisciplinary team with more than 40 years of experience in medical advocacy, research, and nonprofit leadership and grounded in lived patient experience. The campaign will expand access to reliable information, strengthen peer connections, and elevate the patient voice.
A central component of this work includes the development and distribution of educational materials related to Rezolute’s clinical trial. These materials will be shared across AMEND USA’s established communication channels.
AMEND USA is uniquely positioned to deliver information that will remain neutral, factual, and ensuring that patient education remains the primary objective.
The campaign will span across several coordinated phases. We are excited that the initial efforts include a national assessment of patient resource awareness and quality of life, addressing a critical gap in understanding the US MEN community. We look forward to hearing from our community about what is important to them.
Subsequent phases will feature a robust education and awareness campaign, including newsletters, digital content, expert-led webinars, and enhanced mobile-friendly resources. Community engagement efforts will follow, creating opportunities for dialogue through virtual town halls, stakeholder outreach, and the collection of patient experience stories. The campaign will conclude with comprehensive reporting on community needs, campaign impact, and key insights to guide future initiatives.
As part of this engagement, Rezolute will be recognized as a 2026 campaign partner across AMEND USA platforms, including website acknowledgment, newsletter inclusion, and verbal recognition during educational programming. At the same time, AMEND USA maintains full independence over all program content, ensuring that all activities are designed solely to benefit the patient community and not to promote commercial interests.
This partnership represents an important step toward building meaningful, trust-based engagement with a historically underserved and often underrepresented patient population. By investing in education, outreach, and research, this effort will help lay the groundwork for a more informed, connected, and empowered MEN community in the United States.